These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14726401)

  • 21. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
    Simonsson B; Gedde-Dahl T; Markevärn B; Remes K; Stentoft J; Almqvist A; Björeman M; Flogegård M; Koskenvesa P; Lindblom A; Malm C; Mustjoki S; Myhr-Eriksson K; Ohm L; Räsänen A; Sinisalo M; Själander A; Strömberg U; Bjerrum OW; Ehrencrona H; Gruber F; Kairisto V; Olsson K; Sandin F; Nagler A; Nielsen JL; Hjorth-Hansen H; Porkka K;
    Blood; 2011 Sep; 118(12):3228-35. PubMed ID: 21685374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
    Cojbasić I; Macukanović-Golubović L
    Vojnosanit Pregl; 2010 Oct; 67(10):802-6. PubMed ID: 21061842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
    Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
    Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
    [No Abstract]   [Full Text] [Related]  

  • 27. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
    Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
    Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
    Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
    Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate.
    Joshi S; Sunita P; Deshmukh C; Gujral S; Amre P; Nair CN
    Indian J Cancer; 2008; 45(2):45-9. PubMed ID: 18626147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
    Martinelli G; Iacobucci I; Rosti G; Pane F; Amabile M; Castagnetti F; Cilloni D; Soverini S; Testoni N; Specchia G; Merante S; Zaccaria A; Frassoni F; Saglio G; Baccarani M
    Ann Oncol; 2006 Mar; 17(3):495-502. PubMed ID: 16403813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
    Roy L; Guilhot J; Krahnke T; Guerci-Bresler A; Druker BJ; Larson RA; O'Brien S; So C; Massimini G; Guilhot F
    Blood; 2006 Sep; 108(5):1478-84. PubMed ID: 16627756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase.
    Rumpel M; Friedrich T; Deininger MW
    Blood; 2003 Jun; 101(11):4641-3. PubMed ID: 12756164
    [No Abstract]   [Full Text] [Related]  

  • 34. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571).
    Naito K; Mori T; Miyazaki K; Tsukada Y; Ikeda Y; Okamoto S
    Intern Med; 2003 Aug; 42(8):740-2. PubMed ID: 12924504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
    Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
    Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
    Bujassoum S; Rifkind J; Lipton JH
    Leuk Lymphoma; 2004 Feb; 45(2):401-3. PubMed ID: 15101732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.
    Burchert A; Saussele S; Eigendorff E; Müller MC; Sohlbach K; Inselmann S; Schütz C; Metzelder SK; Ziermann J; Kostrewa P; Hoffmann J; Hehlmann R; Neubauer A; Hochhaus A
    Leukemia; 2015 Jun; 29(6):1331-5. PubMed ID: 25712735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
    Cortes J; Giles F; O'Brien S; Thomas D; Garcia-Manero G; Rios MB; Faderl S; Verstovsek S; Ferrajoli A; Freireich EJ; Talpaz M; Kantarjian H
    Blood; 2003 Jul; 102(1):83-6. PubMed ID: 12637317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Imatinib mesylate for chronic myeloid leukemia: in patients with initial treatment versus those with Recombinant Human IFN-α2b treatment failure].
    Jiang JH; Xu WL; Qian WB
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 44(2):179-83. PubMed ID: 26038137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.